ERBB2 and neoplasm: Analyzing the tumor profile of this population, 5.9% of tumors showed HER2 amplification, and 58.9% had high Ki67, while 57.2% of tumors belonged to molecular subtypes different from luminal A. Moreover, 24.7% of tumors presented angiolymphatic emboli.